Income StatementBalance SheetCash FlowSegments
Enterprise Products Partners logo

Enterprise Products Partners Cash Flow Statement

Operating, investing, and financing cash movements

Enterprise Products Partners generated $7.7B in operating cash flow over the trailing twelve months. After $5.5B in capital expenditures, free cash flow was $2.2B. Free cash flow decreased 0.4% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$7.7BNet Cash From Investing (TTM)-$4.8BNet Cash From Financing (TTM)-$3.0BCapital Expenditures (TTM)$5.5BNet Change In Cash (TTM)-$60.0M
Latest FilingQ1 2026
Report Date2026-05-07
Market Cap$85.7B
P/E Ratio14.53
ROE19.62%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Share of Profits (Losses) of Related Party$106.0M$94.0M$92.0M$90.0M$85.0M$76.0M
Other working capital changes—-$14.0M$21.0M-$14.0M$7.0M-$15.0M
Deferred income taxes$22.0M$11.0M$5.0M-$17.0M$47.0M$14.0M
Income (Loss) from Equity Method Investments$106.0M$94.0M$92.0M$90.0M$85.0M$76.0M
Income (Loss) from Equity Method Investments$106.0M$94.0M$92.0M$90.0M$85.0M$76.0M
Income (Loss) from Equity Method Investments$106.0M$94.0M$92.0M$90.0M$85.0M$76.0M
Net cash from operating activities$2.4B$2.3B$2.1B$1.7B$2.5B$1.5B
Net income$1.6B$1.4B$1.5B$1.4B$1.7B$1.5B
Amortization of capitalized software and acquired intangible assets$52.0M$52.0M$52.0M$55.0M$57.0M$58.0M
Amortization of major maintenance costs for reaction-based plants$17.0M$16.0M$15.0M$18.0M$23.0M$25.0M
Depreciation and Accretion$508.0M$511.0M$519.0M$531.0M$546.0M$555.0M
Distributions of earnings from equity method investees$103.0M$88.0M$101.0M$91.0M$84.0M$75.0M
Gain/(loss) on dispositions, net—$2.0M$7.0M$4.0M$1.0M-$1.0M
Equity in earnings (losses) of equity method investees$106.0M$94.0M$92.0M$90.0M$85.0M$76.0M
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital—-$203.0M—$322.0M—$861.0M
Operating lease right-of-use asset amortization$27.0M$28.0M$27.0M$27.0M$27.0M$28.0M
Other amortization expense$51.0M$57.0M$57.0M$56.0M$58.0M$63.0M
Impairment of assets and other charges$6.0M$10.0M$11.0M$17.0M$12.0M$8.0M
Unrealized Gain (Loss) on Derivatives and Commodity Contracts$9.0M-$42.0M$52.0M-$34.0M—-$98.0M
Income (Loss) from Equity Method Investments$106.0M$94.0M$92.0M$90.0M$85.0M$76.0M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from Sales of Assets and Subsidiaries$3.0M$4.0M$11.0M$6.0M$61.0M$596.0M
Capital expenditures$1.1B$1.1B$1.3B$2.0B$1.3B$983.0M
Payment for (Proceeds from) Other Investing Activity$8.0M$4.0M$5.0M$4.0M$12.0M$5.0M
Proceeds from disposition of property, plant and equipment/other$3.0M$4.0M$11.0M$6.0M$61.0M$596.0M
Net cash from investing activities-$2.0B-$1.0B-$1.3B-$1.9B-$1.2B-$381.0M
Dividend Received from Consumer Healthcare JV$13.0M$15.0M$20.0M$21.0M$18.0M$11.0M
Proceeds from sale of PPE and intangibles$3.0M$4.0M$11.0M$6.0M$61.0M$596.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from minority shareholders$57.0M$4.0M$1.0M——$0.0
Distributions to noncontrolling interests$22.0M$13.0M$26.0M$29.0M$25.0M$23.0M
Cash payments made in connection with DERs$11.0M$11.0M$11.0M$11.0M$11.0M$11.0M
Distribution Made to Limited Partner, Cash Distributions Paid$1.1B$1.2B$1.2B$1.2B$1.2B$1.2B
Payments Of Debt Issuance Costs$0.0$12.0M$13.0M$4.0M$13.0M$4.0M
Proceeds from issuances of debt$1.3B$19.1B$30.5B$21.5B$17.2B$22.5B
Other, net$0.0-$80.0M-$5.0M-$3.0M—-$111.0M
Repayments of Debt$1.3B$19.4B$29.3B$20.6B$16.4B$23.0B
Net proceeds from sales of subsidiary shares$57.0M$4.0M$1.0M——$0.0
Payment of Deferred Purchase Consideration$0.0-$80.0M-$5.0M-$3.0M—-$111.0M
Noncontrolling interest transactions and other$0.0-$80.0M-$5.0M-$3.0M—-$111.0M
Proceeds from Minority Shareholders$57.0M$4.0M$1.0M——$0.0
Proceeds from Sale of Noncontrolling Interests$57.0M$4.0M$1.0M——$0.0
Net cash from financing activities-$1.2B-$1.7B-$145.0M-$467.0M-$424.0M-$1.9B
Noncontrolling Interests Activity and Other$0.0-$80.0M-$5.0M-$3.0M—-$111.0M
Proceeds from Minority Shareholders$57.0M$4.0M$1.0M——$0.0
Repurchases of common stock$63.0M$60.0M$110.0M$80.0M$50.0M$116.0M
Proceeds from Minority Shareholders$57.0M$4.0M$1.0M——$0.0

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$1.3B$1.3B$762.0M$0.0$1.2B$486.0M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net increase (decrease) in cash—-$384.0M$642.0M-$664.0M$813.0M-$851.0M